Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.
Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.
Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.
The impact of stigma on cognitive performance; risk factor dissonance among young black MSM; pregnancy and the HIV care continuum; new data on pediatric raltegravir use.
Black transgender women and the HIV care continuum; PrEP uptake potential among trans women; an update on U.S. mother-to-child HIV transmission; is extra measles vaccination necessary?
The benefits of pre-pregnancy HIV treatment initiation for mothers-to-be; HIV diagnoses rise among young U.S. MSM; cost effectiveness of PrEP for heterosexual women; methotrexate and arterial function.
"It is hard to imagine how in 2018 we could be in this situation where women with HIV are being so woefully underserved," Polly Clayden writes.
A recent case study illustrates the complexity of managing women in early stages of pregnancy presenting on a dolutegravir-based regimen, and the need for careful consideration when responding to new data.